Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Poly ADP Ribose Polymerase (PARP) Inhibitor”

38 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 38 results

Testing effectiveness (Phase 2)Ended earlyNCT04377087
What this trial is testing

Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer

Who this might be right for
Ovarian Cancer
Sarah E Taylor 3
Early research (Phase 1)Ended earlyNCT02500901
What this trial is testing

Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC)

Who this might be right for
Metastatic Prostate Cancer
Paul Mathew, MD 2
Testing effectiveness (Phase 2)Study completedNCT01618136
What this trial is testing

An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors

Who this might be right for
Malignant Solid TumourOvarian CancerTriple Negative Breast Cancer+2 more
Eisai Limited 41
Testing effectiveness (Phase 2)Study completedNCT05494580
What this trial is testing

Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer

Who this might be right for
Ovarian CancerOvarian CarcinomaPlatinum-resistant Ovarian Cancer+2 more
Sun Yat-sen University 29
Early research (Phase 1)Study completedNCT03343054
What this trial is testing

Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors

Who this might be right for
NeoplasmsBreast Neoplasms
Pfizer 28
Large-scale testing (Phase 3)Ended earlyNCT03642132
What this trial is testing

Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100)

Who this might be right for
Ovarian Cancer
Pfizer 79
Early research (Phase 1)Ended earlyNCT01226901
What this trial is testing

A Phase I Study of MK-4827 for Treatment of Solid Tumors (MK-4827-005)

Who this might be right for
NeoplasmsSolid Tumors
Merck Sharp & Dohme LLC 3
Testing effectiveness (Phase 2)Active Not RecruitingNCT01012817
What this trial is testing

Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer

Who this might be right for
Metastatic Malignant Solid NeoplasmRecurrent Fallopian Tube CarcinomaRecurrent Ovarian Carcinoma+2 more
National Cancer Institute (NCI) 88
Testing effectiveness (Phase 2)Study completedNCT03326193
What this trial is testing

Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Who this might be right for
Ovarian Neoplasms
Tesaro, Inc. 105
Testing effectiveness (Phase 2)WithdrawnNCT04239014
What this trial is testing

Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.

Who this might be right for
Ovarian Cancer
AstraZeneca
Early research (Phase 1)Ended earlyNCT03944902
What this trial is testing

CB-839 in Combination With Niraparib in Platinum Resistant BRCA -Wild-type Ovarian Cancer Patients

Who this might be right for
Ovarian CancerResistant BRCA Wild-Type Ovarian Cancer
University of Alabama at Birmingham 1
Early research (Phase 1)Ended earlyNCT01127178
What this trial is testing

Study of Poly (ADP-Ribose) Polymerase (PARP) Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors

Who this might be right for
Solid Tumors
Eisai Inc. 12
Testing effectiveness (Phase 2)Study completedNCT00271765
What this trial is testing

INO-1001, an Intravenous PARP (Poly [ADP Ribose] Polymerase) Inhibitor in Acute Heart Attack Patients Undergoing Primary Percutaneous Coronary Intervention

Who this might be right for
Acute Myocardial Infarction
Inotek Pharmaceuticals Corporation 40
Early research (Phase 1)WithdrawnNCT02686008
What this trial is testing

Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCC

Who this might be right for
Squamous Cell Carcinoma of the Head and Neck
Yale University
Testing effectiveness (Phase 2)Study completedNCT01063517
What this trial is testing

Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients

Who this might be right for
Gastric Cancer
AstraZeneca 124
Early research (Phase 1)Study completedNCT00633269
What this trial is testing

Study Assessing Metabolism, Excretion and Pharmacokinetics of a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor in Patients With Solid Metastatic Tumours

Who this might be right for
Neoplasm Metastasis
AstraZeneca 6
Testing effectiveness (Phase 2)Study completedNCT01540565
What this trial is testing

Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
BRCA1 Mutation CarrierBRCA2 Mutation CarrierOvarian Epithelial Tumor+3 more
National Cancer Institute (NCI) 52
Early research (Phase 1)Study completedNCT05002868
What this trial is testing

Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors

Who this might be right for
Solid TumorExtensive-stage Small-cell Lung CancerLocally Advanced Breast Cancer+4 more
Rhizen Pharmaceuticals SA 23
Testing effectiveness (Phase 2)Study completedNCT03574779
What this trial is testing

Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer

Who this might be right for
Ovarian Neoplasms
Tesaro, Inc. 77
Large-scale testing (Phase 3)Ended earlyNCT02470585
What this trial is testing

Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Ovarian CancerOvarian Neoplasm
AbbVie 1,140
Next Page